# A Clinical Trial of Quadrivalent Influenza Virus Split Vaccine (MDCK Cells) for Individuals Aged 6 Months and Above.

> **NCT06342349** · PHASE1 · COMPLETED · sponsor: **Shanghai Institute Of Biological Products** · enrollment: 300 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Quadrivalent influenza virus split vaccine (MDCK cells)
- **BIOLOGICAL:** Quadrivalent influenza virus split vaccine (Chicken embryo)
- **OTHER:** Phosphate buffer solution

## Key facts

- **NCT ID:** NCT06342349
- **Lead sponsor:** Shanghai Institute Of Biological Products
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-30
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2025-02-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06342349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06342349, "A Clinical Trial of Quadrivalent Influenza Virus Split Vaccine (MDCK Cells) for Individuals Aged 6 Months and Above.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06342349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*